# EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)

Study · id `cardio:ct-nct03287609` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03287609](<https://clinicaltrials.gov/study/NCT03287609>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03287609

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 308 participants.

## Technical summary

Registry record NCT03287609. Randomized; quadruple masking; primary purpose treatment. Start 2018-01-23 (actual); primary completion 2019-05-20 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 308 participants (enrolled count; ClinicalTrials.gov record NCT03287609, source copy `cardio:ctgov-nct03287609-2019-08-14`, retrieved 2026-10-31)
- Started: 2018-01-23 (actual) (ClinicalTrials.gov record NCT03287609, source copy `cardio:ctgov-nct03287609-2019-08-14`, retrieved 2026-10-31)
- Primary completion: 2019-05-20 (actual) (ClinicalTrials.gov record NCT03287609, source copy `cardio:ctgov-nct03287609-2019-08-14`, retrieved 2026-10-31)
- Completion: 2019-08-07 (actual) (ClinicalTrials.gov record NCT03287609, source copy `cardio:ctgov-nct03287609-2019-08-14`, retrieved 2026-10-31)
- Countries: Switzerland (ClinicalTrials.gov record NCT03287609, source copy `cardio:ctgov-nct03287609-2019-08-14`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03287609-2019-08-14`, retrieved 2026-10-31)

## The registry's words

- Brief title: EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)
- Acronym: EVOPACS
- Condition: Acute Coronary Syndrome
- Intervention (Drug): Evolocumab 140 mg/mL
- Intervention (Drug): Placebo
- Lead sponsor: Insel Gruppe AG, University Hospital Bern
- Lead sponsor class: OTHER
- Collaborator: Amgen
- Collaborator class: INDUSTRY
- Collaborator: University of Bern
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Evolocumab (`cardio:evolocumab`)
- Registry lists this organization as the lead sponsor: Insel Gruppe AG, University Hospital Bern (`cardio:org-insel-gruppe-ag-university-hospital-bern`)
- Registry lists this organization as a collaborator: Amgen (`cardio:org-amgen`)
- Registry lists this organization as a collaborator: University of Bern (`cardio:org-university-of-bern`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) (`cardio:pubmed-31479722`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: bbb4f0d7c2829401249a078a570e3da3d9dbd8bc907281e567f3b3ec53dac656
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
